Vivos Inc (RDGL) Stock Analysis
Verdict: AVOID
CEO insider buying offers a fragile floor against catastrophic fundamental dilution and a lack of commercial revenue.
Investment score: 32/100
Analysis as of
Is Vivos Inc stock worth reviewing? AI model thesis
Vivos Inc is a speculative medical tech play with minimal revenue ($68k) and severe valuation bloat. While insider buying is a positive signal, the structural financial health is poor.
7-factor investment score
- Valuation: 15/100 (weight 20%)
- Financial Health: 10/100 (weight 15%)
- Technical Momentum: 55/100 (weight 15%)
- Earnings Quality: 20/100 (weight 15%)
- Insider Sentiment: 90/100 (weight 10%)
- Analyst Consensus: 0/100 (weight 10%)
- Risk-Adjusted Return: 30/100 (weight 15%)
Vivos Inc opportunities and risks
What speaks for RDGL
- Consistent Insider Support
What speaks against RDGL
- Terminal Dilution Risk (Cash Runway)走向
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| RDGL | n/a | 545.4x | n/a | -275.6% | -4396.3% | -5.4% |
| DXR | 5.8x | 353.3x | 5.6x | -57.5% | 6105.3% | 0.3% |
| POCI | n/a | 1.3x | n/a | 13.8% | -17.0% | -4.9% |
| QTI | n/a | 4.7x | n/a | 41.7% | -58.9% | -8.7% |
| SRTS | n/a | 2.2x | n/a | 37.7% | -34.5% | -1.5% |
| MYO | n/a | 1.1x | n/a | 66.0% | -36.7% | -39.0% |
| Peer median | n/a | 2.2x | n/a | 37.7% | -34.5% | -4.9% |
Frequently asked questions about Vivos Inc (RDGL)
Is RDGL stock a good investment?
The cached TradeMates AI model rates Vivos Inc as AVOID with an investment score of 32/100. Vivos Inc is a speculative medical tech play with minimal revenue ($68k) and severe valuation bloat. While insider buying is a positive signal, the structural financial health is poor. This is algorithmic model output, not personal investment advice.
Is RDGL stock a buy?
The TradeMates model verdict for RDGL is AVOID with an investment score of 32/100. Treat this as a model signal to review, not a personal buy recommendation.